Forcing dividing cancer cells to die; low-dose drug combinations to prevent spindle pole clustering.


Journal

Apoptosis : an international journal on programmed cell death
ISSN: 1573-675X
Titre abrégé: Apoptosis
Pays: Netherlands
ID NLM: 9712129

Informations de publication

Date de publication:
06 2021
Historique:
accepted: 04 04 2021
pubmed: 20 4 2021
medline: 25 12 2021
entrez: 19 4 2021
Statut: ppublish

Résumé

Mitosis, under the control of the microtubule-based mitotic spindle, is an attractive target for anti-cancer treatments, as cancer cells undergo frequent and uncontrolled cell divisions. Microtubule targeting agents that disrupt mitosis or single molecule inhibitors of mitotic kinases or microtubule motors kill cancer cells with a high efficacy. These treatments have, nevertheless, severe disadvantages: they also target frequently dividing healthy tissues, such as the haematopoietic system, and they often lose their efficacy due to primary or acquired resistance mechanisms. An alternative target that has emerged in dividing cancer cells is their ability to "cluster" the poles of the mitotic spindle into a bipolar configuration. This mechanism is necessary for the specific survival of cancer cells that tend to form multipolar spindles due to the frequent presence of abnormal centrosome numbers or other spindle defects. Here we discuss the recent development of combinatorial treatments targeting spindle pole clustering that specifically target cancer cells bearing aberrant centrosome numbers and that have the potential to avoid resistance mechanism due their combinatorial nature.

Identifiants

pubmed: 33870441
doi: 10.1007/s10495-021-01671-3
pii: 10.1007/s10495-021-01671-3
pmc: PMC8197716
doi:

Substances chimiques

Antineoplastic Agents 0
Drug Combinations 0
Histone Deacetylase Inhibitors 0
Protein Kinase Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

248-252

Références

Mol Oncol. 2020 Nov;14(11):2894-2919
pubmed: 33021054
Cancer Res. 2002 Apr 1;62(7):1935-8
pubmed: 11929805
Oncotarget. 2015 Oct 13;6(31):31104-18
pubmed: 26418751
Mol Biol Cell. 2014 Sep 15;25(18):2677-81
pubmed: 25213191
Nature. 2009 Jul 9;460(7252):278-82
pubmed: 19506557
EMBO Rep. 2012 Jun 01;13(6):515-27
pubmed: 22614003
Cancers (Basel). 2020 Oct 28;12(11):
pubmed: 33126775
Nat Rev Cancer. 2010 Mar;10(3):194-204
pubmed: 20147901
Nat Rev Mol Cell Biol. 2013 Jan;14(1):25-37
pubmed: 23258294
Nat Biotechnol. 2009 Jul;27(7):659-66
pubmed: 19581876
Cell Death Dis. 2012 Oct 18;3:e411
pubmed: 23076219
Cancers (Basel). 2019 Oct 22;11(10):
pubmed: 31652588
Nat Rev Mol Cell Biol. 2010 Feb;11(2):91-102
pubmed: 20068571
Nat Commun. 2018 Mar 28;9(1):1258
pubmed: 29593297
Trends Cell Biol. 2018 Oct;28(10):776-792
pubmed: 29871823
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9819-24
pubmed: 12119403
Sci Transl Med. 2014 Mar 26;6(229):229ra43
pubmed: 24670687
J Cell Biol. 2018 Jul 2;217(7):2353-2363
pubmed: 29739803
Nat Protoc. 2016 Feb;11(2):302-15
pubmed: 26766116
Clin Cancer Res. 2012 Jan 1;18(1):51-63
pubmed: 22215906
Biochim Biophys Acta. 2008 Sep;1786(1):32-40
pubmed: 18549824
Adv Exp Med Biol. 2017;1002:125-152
pubmed: 28600785
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell Death Dis. 2014 Nov 20;5:e1538
pubmed: 25412316
Curr Opin Cell Biol. 2013 Dec;25(6):780-5
pubmed: 23890995
Sci Rep. 2015 Sep 29;5:14508
pubmed: 26416286
Cancer Res. 2016 Nov 15;76(22):6690-6700
pubmed: 27634760
Genes Dev. 2008 Aug 15;22(16):2189-203
pubmed: 18662975
Oncotarget. 2016 Mar 8;7(10):11310-20
pubmed: 26824502
Science. 2005 Jan 7;307(5706):127-9
pubmed: 15637283
Br J Cancer. 2019 Jul;121(2):139-149
pubmed: 31235865
Genes Dev. 2012 Dec 15;26(24):2709-23
pubmed: 23249734
Molecules. 2018 May 13;23(5):
pubmed: 29757235

Auteurs

Eloise Ducrey (E)

School of Pharmaceutical Sciences, Faculty of Sciences, University of Geneva, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland.
Translational Research Center in Oncohaematology, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland.

Cédric Castrogiovanni (C)

Translational Research Center in Oncohaematology, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland.
Department of Cell Physiology and Metabolism, University of Geneva Medical School, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland.

Patrick Meraldi (P)

Translational Research Center in Oncohaematology, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland. Patrick.Meraldi@unige.ch.
Department of Cell Physiology and Metabolism, University of Geneva Medical School, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland. Patrick.Meraldi@unige.ch.

Patrycja Nowak-Sliwinska (P)

School of Pharmaceutical Sciences, Faculty of Sciences, University of Geneva, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland. Patrycja.Nowak-Sliwinska@unige.ch.
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland. Patrycja.Nowak-Sliwinska@unige.ch.
Translational Research Center in Oncohaematology, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland. Patrycja.Nowak-Sliwinska@unige.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH